Related Experiment Videos
SR31747A: a peripheral sigma ligand with potent antitumor activities
Pierre Casellas1, Sylvaine Galiegue, Bernard Bourrie
1Immunology-Oncology Department, Sanofi-Synthelabo Recherche, 371 rue du Professeur Joseph Blayac, 34184 Montpellier Cedex 04, France. pierre.casellas@sanofi-synthelabo.com
Anti-Cancer Drugs
|April 13, 2004
Summary
SR31747A, a novel peripheral sigma ligand, demonstrates dual immunomodulatory and antiproliferative effects. Preclinical studies show significant reduction in tumor incidence and growth, supporting its potential in prostate cancer treatment.
Area of Science:
- Pharmacology
- Immunology
- Oncology
Background:
- SR31747A is a peripheral sigma ligand targeting SRBP-1, sigma-2, HSI, and SRBP-2.
- It exhibits both immunomodulatory and antiproliferative properties.
Purpose of the Study:
- To review recent literature on SR31747A in cancer treatment.
- To focus on preclinical in vivo data and mode of action studies.
Main Methods:
- Evaluation of SR31747A's effects on lymphocyte proliferation and cytokine expression.
- Assessment of in vivo efficacy against inflammatory conditions and tumor models.
- Analysis of time- and concentration-dependent inhibition of tumor cell lines.
Main Results:
- SR31747A modulates pro- and anti-inflammatory cytokines and protects against various inflammatory conditions.
- It inhibits tumor cell proliferation in vitro and reduces tumor incidence and growth by over 40% in vivo in mouse models.
- The molecule is currently in phase IIb clinical trials for prostate cancer.
Conclusions:
- SR31747A possesses significant preclinical antitumoral and immunomodulatory activities.
- Its dual mechanism suggests potential as a therapeutic agent for cancer and inflammatory diseases.